GeneNews BreastSentry

GeneNews has launched BreastSentry, a new risk stratification test for breast cancer. The company will offer the test in its Virginia-based clinical reference lab. The test measures the fasting plasma levels of two biomarkers in the blood, proneurotensin and proenkephalin, which are highly predictive of a woman's risk for developing breast cancer, the company said. It is intended for use in average risk women who have no family history of breast cancer, especially for women who have dense breast tissue, to better evaluate when patients may require further screening.